Ibrutinib in B-cell lymphoma
Advani R H et al. JCO 2013;31:88-94
Responders (n/N)
Mantle cell
7/9
CLL/SLL
11/16
FL
6/16
DLBCL
2/7
WM
3/4
ORR
60%
N=56. Median 3 (1-10) prior
therapies